Please ensure Javascript is enabled for purposes of website accessibility
Gilead's $2,340 Price for Coronavirus Drug Draws Criticism
gvw_ap_news
By Associated Press
Published 5 years ago on
June 29, 2020

Share

The maker of a drug shown to shorten recovery time for severely ill COVID-19 patients says it will charge $2,340 for a typical treatment course for people covered by government health programs in the United States and other developed countries.

Gilead Sciences announced the price Monday for remdesivir, and said the price would be $3,120 for patients with private insurance. The amount that patients pay out of pocket depends on insurance, income and other factors.
Gilead Sciences announced the price Monday for remdesivir, and said the price would be $3,120 for patients with private insurance. The amount that patients pay out of pocket depends on insurance, income and other factors.
“We’re in uncharted territory with pricing a new medicine, a novel medicine, in a pandemic,” Gilead’s chief executive, Dan O’Day, told The Associated Press.
“We believe that we had to really deviate from the normal circumstances” and price the drug to ensure wide access rather than based solely on value to patients, he said.
However, the price was swiftly criticized; a consumer group called it “an outrage” because of the amount taxpayers invested toward the drug’s development.
The treatment courses that the company has donated to the U.S. and other countries will run out in about a week, and the prices will apply to the drug after that, O’Day said.
In the U.S., federal health officials have allocated the limited supply to states, but that agreement with Gilead will end after September. They said Monday that the government has secured more than 500,000 additional courses that Gilead will produce starting in July to supply to hospitals through September, and stressed that that does not mean the government actually was acquiring that much, just ensuring the availability.

Drug Interferes With Coronavirus’ Ability to Copy Its Genetic Material

“We should have sufficient supply … but we have to make sure it’s in the right place at the right time,” O’Day said
In 127 poor or middle-income countries, Gilead is allowing generic makers to supply the drug; two countries are doing that for around $600 per treatment course.
Remdesivir’s price has been highly anticipated since it became the first medicine to show benefit in the pandemic, which has killed more than half a million people globally in six months.
The drug interferes with the coronavirus’s ability to copy its genetic material. In a U.S. government-led study, remdesivir shortened recovery time by 31% — 11 days on average versus 15 days for those given just usual care. It had not improved survival according to preliminary results after two weeks of followup; results after four weeks are expected soon.
The Institute for Clinical and Economic Review, a nonprofit group that analyzes drug prices, said remdesivir would be cost-effective in a range of $4,580 to $5,080 if it saved lives. But recent news that a cheap steroid called dexamethasone improves survival means remdesivir should be priced between $2,520 and $2,800, the group said.
“This is a high price for a drug that has not been shown to reduce mortality,” Dr. Steven Nissen of the Cleveland Clinic said in an email. “Given the serious nature of the pandemic, I would prefer that the government take over production and distribute the drug for free. It was developed using significant taxpayer funding.”

Drug Has Emergency Use Authorization in the US

Peter Maybarduk, a lawyer at the consumer group Public Citizen, called the price “an outrage.”

While it may be a sticker shock for many, “from the health system perspective, if remdesivir can shorten duration of hospitalization by four days, then the medicine provides a reasonable value,” Dr. David Boulware, an infectious disease specialist at the University of Minnesota, said in an email.
“Remdesivir should be in the public domain” because the drug received at least $70 million in public funding toward its development, he said.
“The price puts to rest any notion that drug companies will ‘do the right thing’ because it is a pandemic,” Dr. Peter Bach, a health policy expert at Memorial Sloan Kettering Cancer Center in New York said in an email. “The price might have been fine if the company had demonstrated that the treatment saved lives. It didn’t.”
While it may be a sticker shock for many, “from the health system perspective, if remdesivir can shorten duration of hospitalization by four days, then the medicine provides a reasonable value,” Dr. David Boulware, an infectious disease specialist at the University of Minnesota, said in an email.
O’Day said that shortening hospitalization saves about $12,000 per patient. Gilead says it will have spent $1 billion on developing and making the drug by the end of this year.
The drug has emergency use authorization in the U.S. and Gilead has applied for full approval.

RELATED TOPICS:

DON'T MISS

What Are Fresno Real Estate Experts Predicting for 2025 and Beyond?

DON'T MISS

First California EV Mandates Hit Automakers This Year. Most Are Not Even Close

DON'T MISS

Trump Poised to Offer Saudi Arabia Over $100 Billion Arms Package, Sources Say

DON'T MISS

Lights, Camera, Board Vote: Fresno Unified’s Carefully Choreographed Production

DON'T MISS

US Farm Agency Withdraws Proposal Aimed at Lowering Salmonella Risks in Poultry

DON'T MISS

On Major Economic Decisions, Trump Blinks, and Then Blinks Again

DON'T MISS

Candi Is the Dandy to Add a Little Sweetness to Your Life

DON'T MISS

How Trump Tariffs Could Upend California Farms, Wine Businesses, and Ports

DON'T MISS

Tulare Man Sentenced to State Prison for DUI Crash That Injured Two Women

DON'T MISS

Judge Partly Blocks Trump Order Seeking to Overhaul US Elections

DON'T MISS

Two From Search Group That Uncovered Mexico’s ‘Ranch of Horror’ Killed

DON'T MISS

US Warns States They Could Lose Transportation Funding Over Immigration, DEI Policies

UP NEXT

Long Wait Is Over for Cam Ward, Travis Hunter and Other Draft Prospects Joining the NFL

UP NEXT

Golden State’s Jimmy Butler Injured in Game 2 Loss, His Status for Game 3 Unknown

UP NEXT

Jalen Green Makes Eight 3s to Help Rockets Even Series With Warriors

UP NEXT

US Justice Department Directs Investigations Over Gender-Affirming Care

UP NEXT

US Justice Department Cancels Hundreds of Grants for Police, Crime Victims

UP NEXT

Yelich’s 5th Career Slam and Bauers’ 2-Run Homer Power the Brewers to Win Over the Giants

UP NEXT

Happ Hits Game-Ending Single in the 10th as the Cubs Rally Past Dodgers

UP NEXT

Trump: No Plans to Fire Fed Chair Powell, but Wants Lower Rates

UP NEXT

Top Producer at ’60 Minutes’ Quits Amid Trump Lawsuit Pressure

UP NEXT

Israeli Strikes Kill 17 in Gaza and Destroy Heavy Equipment Needed to Clear Rubble

On Major Economic Decisions, Trump Blinks, and Then Blinks Again

2 hours ago

Candi Is the Dandy to Add a Little Sweetness to Your Life

2 hours ago

How Trump Tariffs Could Upend California Farms, Wine Businesses, and Ports

2 hours ago

Tulare Man Sentenced to State Prison for DUI Crash That Injured Two Women

4 hours ago

Judge Partly Blocks Trump Order Seeking to Overhaul US Elections

4 hours ago

Two From Search Group That Uncovered Mexico’s ‘Ranch of Horror’ Killed

4 hours ago

US Warns States They Could Lose Transportation Funding Over Immigration, DEI Policies

4 hours ago

Don’t Miss Out! Tower District’s Porchfest Festival Is Saturday

4 hours ago

Shooter in 2022 Chicago-Area Parade Massacre Sentenced to Life in Prison

5 hours ago

Fresno Stabbing Leaves Son Dead, Father Charged With Murder

5 hours ago

Trump Poised to Offer Saudi Arabia Over $100 Billion Arms Package, Sources Say

WASHINGTON/RIYADH (Reuters) – The United States is poised to offer Saudi Arabia an arms package worth well over $100 billion, six sour...

42 minutes ago

President Donald Trump delivers remarks during an 'Unleashing American Energy' event at the Department of Energy in Washington, U.S., June 29, 2017. (REUTERS File)
42 minutes ago

Trump Poised to Offer Saudi Arabia Over $100 Billion Arms Package, Sources Say

1 hour ago

Lights, Camera, Board Vote: Fresno Unified’s Carefully Choreographed Production

Chickens sit at a poultry farm. March 12, 2025. (REUTERS/Diego Vara/File Photo)
2 hours ago

US Farm Agency Withdraws Proposal Aimed at Lowering Salmonella Risks in Poultry

2 hours ago

On Major Economic Decisions, Trump Blinks, and Then Blinks Again

Candi, GV Wire's Adoptable Cat of the Week
2 hours ago

Candi Is the Dandy to Add a Little Sweetness to Your Life

2 hours ago

How Trump Tariffs Could Upend California Farms, Wine Businesses, and Ports

Maxwell Barrios, 28, of Tulare, was sentenced to over four years in state prison on Wednesday, April 23, 2025, for a 2023 DUI crash that seriously injured two women, including one who required a partial arm amputation. (Tulare County DA)
4 hours ago

Tulare Man Sentenced to State Prison for DUI Crash That Injured Two Women

People vote in the 2024 U.S. presidential election on Election Day in Columbus, Ohio, U.S., November 5, 2024. (REUTERS/Megan Jelinger/File Photo)
4 hours ago

Judge Partly Blocks Trump Order Seeking to Overhaul US Elections

Help continue the work that gets you the news that matters most.

Search

Send this to a friend